CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance https://www.globenewswire.com/news-release/2021/07/29/2271713/31386/en/CareDx-Reports-77-Revenue-Growth-for-Second-Quarter-of-2021-and-Increases-Full-Year-Revenue-Guidance.html ... Recent Highlights: • Achieved total revenue of $74.2 million for the three months ended June 30, 2021, increasing 77% year-over-year • Total AlloSure and AlloMap patient results provided in the quarter were approximately 37,400, which includes approximately 6,600 AlloSure Heart patient results • As of June 30, 2021, over 65 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol. In addition, TX Connect now manages more than 29,000 transplant referrals to over 50 transplant centers from more than 800 dialysis centers and community nephrology practices • Presented positive data from first 1,000 patients from KOAR Study demonstrating higher 1-year graft survival and reduction in biopsies through ARTS surveillance ...

CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients https://www.globenewswire.com/news-release/2021/07/26/2268442/31386/en/CareDx-Launches-ACROBAT-Study-to-Potentially-Change-Care-Paradigm-for-Stem-Cell-Transplant-Patients.html ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ...

CareDx To Acquire Transplant Hero Medication Management Application https://www.globenewswire.com/news-release/2021/06/08/2243452/31386/en/CareDx-To-Acquire-Transplant-Hero-Medication-Management-Application.html Acquisition adds to growing digital portfolio for patients and transplant centers

CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance https://www.globenewswire.com/news-release/2021/06/07/2242580/31386/en/CareDx-Presents-Landmark-KOAR-1000-Data-Demonstrating-Higher-1-Year-Graft-Survival-and-Reduction-in-Biopsies-through-ARTS-Surveillance.html KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled

CareDx Advances Artificial Intelligence in Transplantation Partnership with OrganX to develop decision support systems https://www.globenewswire.com/news-release/2021/06/03/2241712/31386/en/CareDx-Advances-Artificial-Intelligence-in-Transplantation.html CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress https://markets.businessinsider.com/news/stocks/caredx-presents-groundbreaking-allosure-data-at-the-2021-american-transplant-congress-1030494698

CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare https://www.globenewswire.com/news-release/2021/06/01/2239480/0/en/CareDx-Starts-Enrollment-in-MAPLE-a-Multi-modal-Multi-center-Prospective-Study-of-LiverCare.html Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients

CareDx Announces Strategic Minority Investment in Miromatrix https://www.globenewswire.com/news-release/2021/05/28/2238527/0/en/CareDx-Announces-Strategic-Minority-Investment-in-Miromatrix.html Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs

https://www.globenewswire.com/news-release/2021/05/05/2223806/0/en/CareDx-Reports-First-Quarter-2021-Results.html

CareDx Announces Palmetto MolDx Finalized Local Coverage Determination 'Molecular Testing For Solid Organ Allograft Rejection' https://pub.webull.com/us/news-html/a66afe0fa5cb42f8a1c81b0cb9086b6d.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en

CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients https://www.biospace.com/article/releases/caredx-to-debut-multicenter-data-on-allosure-lung-an-analytically-and-clinically-validated-biomarker-of-graft-injury-for-lung-transplant-patients/ Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting ...today announced that experts will be presenting 22 clinical abstract presentations at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, to be held between April 24-28, 2021.  ...

https://www.globenewswire.com/news-release/2021/04/08/2206544/31386/en/CareDx-Announces-New-HLA-Typing-Service-Offering-for-Research-Purposes.html

CareDx Strengthens Bioinformatics Capabilities with Acquisition of BFS Molecular https://www.globenewswire.com/news-release/2021/03/17/2194384/0/en/CareDx-Strengthens-Bioinformatics-Capabilities-with-Acquisition-of-BFS-Molecular.html

https://pub.webull.com/us/news-html/64049e90a6b142acb612869f513c193f.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en Raymond James analyst Andrew Cooper maintains CareDx (NASDAQ:CDNA) with a Strong Buy and lowers the price target from $101 to $98.

CareDx Expands into the Pre-Transplant Kidney Space through TX Connect https://www.globenewswire.com/news-release/2021/02/25/2182278/0/en/CareDx-Expands-into-the-Pre-Transplant-Kidney-Space-through-TX-Connect.html TX Connect adds 19,000 patient referrals for kidney transplant and continues CareDx’s focus on the patient journey ...

CareDx Reports Fourth Quarter and Full Year 2020 Results https://finance.yahoo.com/news/caredx-reports-fourth-quarter-full-210100080.html Recent Highlights: • Achieved total revenue of $58.6 million for the three months ended December 31, 2020, increasing 64% over prior year fourth quarter • Delivered record full year revenue of $192.2 million, an increase of 51% compared with full year 2019 revenue • Provided over 25,000 patient results in the fourth quarter and approximately 79,000 patient results in 2020 • Generated GAAP net loss of $3.5 million, non-GAAP net income of $4.3 million, and positive adjusted EBITDA of $4.9 million in the fourth quarter • As of December 31, 2020, over 55 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol • Received Medicare reimbursement pricing for AlloSure Heart       ....

BRIEF-Ark Investment Management Llc Reports A Passive Stake Of 10.54% In CareDx Inc As Of Jan. 31, 2021 https://pub.webull.com/us/news-html/12ba70cf914647c5afe835a27cedb190.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en Caredx jumps 10% after Cathie Wood’s ARK takes 10.5% stake https://seekingalpha.com/news/3660957-caredx-stock-rises-10-on-ownership-disclosure • ARK Investment Management discloses 5.19M share ownership in CareDX (NASDAQ:CDNA), representing 10.54%. • The shares contain voting power.